Off-the-Shelf Universal CAR-T Therapy represents a paradigm shift in cancer immunotherapy, providing pre-manufactured, ready-to-administer chimeric antigen receptor T-cell treatments that eliminate the need for patient-specific customization. Developed by leading institutions including the University of Pennsylvania and Cellectis, this approach uses CRISPR gene editing to create universal CAR-T cells from healthy donor cells, removing the risk of immune rejection while maintaining potent anti-tumor activity. Unlike traditional autologous CAR-T therapy, which requires 2-4 weeks of manufacturing and costs upwards of $475,000, off-the-shelf CAR-T can be administered within 72 hours at a cost below $200,000. The process involves editing donor T cells to disable the TCR (T-cell receptor) and HLA (human leukocyte antigen) molecules, preventing graft-versus-host disease and immune rejection, while inserting a tumor-specific CAR. Clinical trials conducted in 2026 for acute lymphoblastic leukemia showed a 92% remission rate, comparable to autologous CAR-T but with significantly reduced treatment time and cost. The FDA approved the first off-the-shelf CAR-T therapy in March 2026 for non-Hodgkin lymphoma, with applications expanding to solid tumors through combination with immune checkpoint inhibitors. This innovation has the potential to democratize access to CAR-T therapy globally, particularly in developing countries where personalized treatment is financially inaccessible.